SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California

CHINO HILLS, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today its new manufacturing facility at Carlsbad. 

SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California.

The company is excited to announce the opening of a new facility in Carlsbad to meet the growing demand for its products. This facility will handle the orders that SOHM has received and expects to receive in the near future, while its main facility in downtown San Diego undergoes renovation to become fully operational. SOHM aims to complete the engineering batches produced in the San Diego facility by Q1 2024. This expansion is part of the company’s strategic plan to enhance its production capacity and efficiency.

The new Carlsbad, California, facility will feature adequate space to manufacture topical products and SOHM’s operations, and 2,500 square feet allocated to storage of finished products. (CDMO:  Contract Development and Manufacturing Organization.)

This facility will have an initial daily capacity of 500 gallons (1,892 liters) with initial manufactured products of topicals but will be expected to add soft-gel suppositories to its capacity by end of Q1 2024 /beginning of Q2 2024.

As of this press release, the facility is near-final. Full cGMP manufacturing capacity is expected to be completed by December 2023.

The bio and pharma contract development and manufacturing (“CDMO”) market is $223 billion as of 2023 and is expected to grow to $309 billion by 2028, implying a 6.74% CAGR between 2018 - 2028 (compounded annual growth rate). The largest CDMO market is North America with the largest production market being Asia, according to Mordor Intelligence.

Source: Link to Mordor Intelligence.com (industry report 2023).

ABBIE is SOHM’s non-viral gene-editing bio-kits. Large-scale commercial manufacturing of ABBIE gene editing kits will be supported in SOHM’s Southern California manufacturing facilities.

“I am very proud to launch this facility with our SOHM team members. This Carlsbad facility is conveniently located right at the mid-way between two importing commercial hubs: Los Angeles and San Diego. Our location on major land shipping routes will play an important role in maintaining our competitive pricing edge in material sourcing and final products to our clients. Many people do not know this, but Carlsbad is also the home to many biotech and pharma companies who routinely rely on CDMO operators like SOHM for their bio-manufacturing needs,” says Dr. David Aguilar, COO.